HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry

被引:10
|
作者
Cordova, Claudio [1 ,2 ]
Munoz, Roberto [2 ,3 ]
Olivares, Rodrigo [3 ,4 ]
Minonzio, Jean-Gabriel [2 ,3 ,4 ,5 ]
Lozano, Carlo [6 ]
Gonzalez, Paulina [6 ,7 ]
Marchant, Ivanny [8 ]
Gonzalez-Arriagada, Wilfredo [9 ,10 ]
Olivero, Pablo [1 ,2 ]
机构
[1] Univ Valparaiso, Fac Med, Cell Funct & Struct Lab EFC Lab, 2664 Hontaneda, Valparaiso 2341386, Chile
[2] Univ Valparaiso, Fac Engn, PhD Program Hlth Sci & Engn, Valparaiso 2362735, Chile
[3] Univ Valparaiso, Fac Engn, Sch Informat Engn, Valparaiso 2362735, Chile
[4] Univ Valparaiso, Fac Engn, Ctr Res & Dev Hlth Engn, Valparaiso 2362735, Chile
[5] Univ Valparaiso, Fac Engn, Millennium Inst Intelligent Healthcare iHEALTH, Valparaiso 2362735, Chile
[6] Carlos Van Buren Hosp, Pathol Anat Serv, Valparaiso 2340105, Chile
[7] Andres Bello Natl Univ UNAB, Sch Med Technol, Vina Del Mar 2520000, Chile
[8] Univ Valparaiso, Fac Med, Med Modeling Lab, Valparaiso 2362735, Chile
[9] Univ Los Andes, Fac Dent, Santiago 7620086, Chile
[10] Univ Los Andes, Biomed Res & Innovat Ctr CIIB, Santiago 7620086, Chile
关键词
breast cancer; HER2; IHC; ML; SHAP; RECEPTOR; EXPRESSION; WOMEN; CONSENSUS;
D O I
10.3892/ol.2022.13630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immunohistochemical (IHC) evaluation of epidermal growth factor 2 (HER2) for the diagnosis of breast cancer is still qualitative with a high degree of inter-observer variability, and thus requires the incorporation of complementary techniques such as fluorescent in situ hybridization (FISH) to resolve the diagnosis. Implementing automatic algorithms to classify IHC biomarkers is crucial for typifying the tumor and deciding on therapy for each patient with better performance. The present study aims to demonstrate that, using an explainable Machine Learning (ML) model for the classification of HER2 photomicrographs, it is possible to determine criteria to improve the value of IHC analysis. We trained a logistic regression-based supervised ML model with 393 IHC microscopy images from 131 patients, to discriminate between upregulated and normal expression of the HER2 protein. Pathologists' diagnoses (IHC only) vs. the final diagnosis complemented with FISH (IHC + FISH) were used as training outputs. Basic performance metrics and receiver operating characteristic curve analysis were used together with an explainability algorithm based on Shapley Additive exPlanations (SHAP) values to understand training differences. The model could discriminate amplified IHC from normal expression with better performance when the training output was the IHC + FISH final diagnosis (IHC vs. IHC + FISH: area under the curve, 0.94 vs. 0.81). This may be explained by the increased analytical impact of the membrane distribution criteria over the global intensity of the signal, according to SHAP value interpretation. The classification model improved its performance when the training input was the final diagnosis, downplaying the weighting of the intensity of the IHC signal, suggesting that to improve pathological diagnosis before FISH consultation, it is necessary to emphasize subcellular patterns of staining.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Effect of Prolonged Fixation Time on ER, PR and Her2 Immunohistochemistry in Breast Cancer
    Dilly, M.
    Karanian-Philippe, M.
    Croce, S.
    Jacquemart, R.
    Petersen, M. C.
    MacGrogan, G.
    LABORATORY INVESTIGATION, 2014, 94 : 45A - 45A
  • [32] Performance Evaluation of Artificial Intelligence in Automated Assessment of HER2 Immunohistochemistry in Breast Cancer
    Wu, Si
    Li, Xiang
    Miao, Jiaxian
    Xian, Dongyi
    Wei, Weiwei
    Liu, Yueping
    LABORATORY INVESTIGATION, 2024, 104 (03) : S304 - S305
  • [33] Relationship between survival to breast cancer and level of HER2 expression by immunohistochemistry.
    Provencher, Louise
    Diorio, Caroline
    Desbiens, Christine
    Poirier, Brigitte
    Poirier, Eric
    Boudreau, Dominique
    Doyle, Catherine
    Popa, Ion
    Gagne, Isabelle
    Hogue, Jean-Charles
    Lemieux, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+Breast Cancer With Early Recurrence
    Yamashita, Hiroko
    Ishida, Naoko
    Hatanaka, Yutaka
    Hagio, Kanako
    Oshino, Tomohiro
    Takeshita, Takashi
    Kanno-Okada, Hiromi
    Shimizu, Ai
    Hatanaka, Kanako C.
    Matsuno, Yoshihiro
    ANTICANCER RESEARCH, 2020, 40 (02) : 645 - 652
  • [35] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    MODERN PATHOLOGY, 2019, 32
  • [36] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    LABORATORY INVESTIGATION, 2019, 99
  • [37] HER2 Status in Breast biopsy: How reliable is Immunohistochemistry?
    Lebeau, A.
    Turzynski, A.
    Braun, S.
    Behrhof, W.
    Fleige, B.
    Schmitt, W.
    Grob, T.
    Burkhardt, L.
    Jackisch, C.
    Thomssen, C.
    Mueller, V.
    Untch, M.
    ONKOLOGIE, 2010, 33 : 13 - 13
  • [38] FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma
    Okaly, Geeta Vikram Patil
    Panwar, Dipti
    Lingappa, Kavitha Bidadli
    Kumari, Prasanna
    Anand, Abhishek
    Kumar, Prashantha
    Chikkalingaiah, Manju Hosur
    Kumar, Rekha Vijay
    INDIAN JOURNAL OF CANCER, 2019, 56 (02) : 119 - 123
  • [39] Risk Classification For Breast Cancer Diagnosis Using HER2 Testing
    Aktan, Pinar Ece
    Hatipoglu, Gokhan
    Arica, Nafiz
    2016 24TH SIGNAL PROCESSING AND COMMUNICATION APPLICATION CONFERENCE (SIU), 2016, : 2133 - 2136
  • [40] Characterization of the HER2 status on circulating breast cancer cells
    Alix-Panabieres, C.
    Riethdorf, S.
    Fehm, T.
    Vendrell, J-P
    Pantel, K.
    CANCER RESEARCH, 2009, 69 (02) : 306S - 306S